Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.44
HAE's Cash-to-Debt is ranked lower than
75% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. HAE: 0.44 )
Ranked among companies with meaningful Cash-to-Debt only.
HAE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 0.94 Max: N/A
Current: 0.44
Equity-to-Asset 0.60
HAE's Equity-to-Asset is ranked higher than
52% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. HAE: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
HAE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53  Med: 0.69 Max: 0.84
Current: 0.6
0.53
0.84
Piotroski F-Score: 5
Altman Z-Score: 3.88
Beneish M-Score: -3.20
WACC vs ROIC
7.13%
-1.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -2.19
HAE's Operating Margin % is ranked lower than
54% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. HAE: -2.19 )
Ranked among companies with meaningful Operating Margin % only.
HAE' s Operating Margin % Range Over the Past 10 Years
Min: -4.83  Med: 9.26 Max: 16.34
Current: -2.19
-4.83
16.34
Net Margin % -2.96
HAE's Net Margin % is ranked lower than
55% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. HAE: -2.96 )
Ranked among companies with meaningful Net Margin % only.
HAE' s Net Margin % Range Over the Past 10 Years
Min: -6.12  Med: 6.7 Max: 11.82
Current: -2.96
-6.12
11.82
ROE % -3.55
HAE's ROE % is ranked lower than
57% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. HAE: -3.55 )
Ranked among companies with meaningful ROE % only.
HAE' s ROE % Range Over the Past 10 Years
Min: -7.18  Med: 7.3 Max: 12.5
Current: -3.55
-7.18
12.5
ROA % -2.02
HAE's ROA % is ranked lower than
54% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. HAE: -2.02 )
Ranked among companies with meaningful ROA % only.
HAE' s ROA % Range Over the Past 10 Years
Min: -3.96  Med: 5.47 Max: 10.03
Current: -2.02
-3.96
10.03
ROC (Joel Greenblatt) % -3.47
HAE's ROC (Joel Greenblatt) % is ranked lower than
54% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. HAE: -3.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HAE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7.84  Med: 20.75 Max: 38.15
Current: -3.47
-7.84
38.15
3-Year Revenue Growth Rate -1.40
HAE's 3-Year Revenue Growth Rate is ranked lower than
61% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. HAE: -1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HAE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.4  Med: 7.85 Max: 15
Current: -1.4
-1.4
15
3-Year EBITDA Growth Rate -17.70
HAE's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. HAE: -17.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HAE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.75 Max: 105.5
Current: -17.7
0
105.5
GuruFocus has detected 5 Warning Signs with Haemonetics Corp $HAE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HAE's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

HAE Guru Trades in Q2 2016

Paul Tudor Jones 16,898 sh (New)
Joel Greenblatt 39,575 sh (New)
Jim Simons 777,300 sh (+180.41%)
Ken Fisher 257,467 sh (+17.50%)
» More
Q3 2016

HAE Guru Trades in Q3 2016

Steven Cohen 685,800 sh (New)
Jim Simons 883,600 sh (+13.68%)
Ken Fisher 267,712 sh (+3.98%)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2016

HAE Guru Trades in Q4 2016

Paul Tudor Jones 12,246 sh (New)
Jim Simons 895,200 sh (+1.31%)
Ken Fisher 267,667 sh (-0.02%)
Steven Cohen 82,058 sh (-88.03%)
» More
Q1 2017

HAE Guru Trades in Q1 2017

Joel Greenblatt 15,808 sh (New)
Columbia Wanger 586,290 sh (New)
Paul Tudor Jones 27,983 sh (+128.51%)
Steven Cohen Sold Out
Jim Simons 818,600 sh (-8.56%)
Ken Fisher 241,967 sh (-9.60%)
» More
» Details

Insider Trades

Latest Guru Trades with HAE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:TOPCF, NAS:PODD, NAS:MMSI, OTCPK:ANSLF, NYSE:HYH, NAS:NXTM, NYSE:GKOS, NAS:ICUI, NYSE:CMD, NAS:NVCR, NAS:ATRI, NAS:LMNX, NAS:OSUR, NAS:IRTC, NAS:ATRC, NAS:ANGO, NAS:LMAT, NAS:MLAB, AMEX:CRHM, NAS:PLSE » details
Traded in other countries:HAZ.Germany,
Headquarter Location:USA
Haemonetics Corp is a health care company.It provides products to customers involved in the processing,handling and analysis of blood and portfolio of integrated devices and information management tools to improve clinical outcomes & reduce costs.

Haemonetics sells products used to process, handle, and analyze blood. The firm sells products in four categories: Plasma, Blood Center, Hospital, and Software Solutions. The Plasma business includes plasma collection devices and disposables. The Blood Center business sells blood collection and processing devices and disposables. The Hospital business sells surgical blood salvage and blood demand diagnostic devices and disposables. The Software Solutions business provides information technology platforms and consulting services to the plasma, blood, and hospital markets. Haemonetics generates the majority of its revenue in the United States.

Top Ranked Articles about Haemonetics Corp

Weekly CEO Buys Highlights Insiders invest in Penske Automotive, Haemonetics, Gogo, Hanesbrands
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 25.91
HAE's Forward PE Ratio is ranked lower than
59% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. HAE: 25.91 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 2.90
HAE's PB Ratio is ranked higher than
59% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. HAE: 2.90 )
Ranked among companies with meaningful PB Ratio only.
HAE' s PB Ratio Range Over the Past 10 Years
Min: 1.84  Med: 2.53 Max: 3.4
Current: 2.9
1.84
3.4
PS Ratio 2.40
HAE's PS Ratio is ranked higher than
59% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. HAE: 2.40 )
Ranked among companies with meaningful PS Ratio only.
HAE' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 2.36 Max: 3.41
Current: 2.4
1.47
3.41
Price-to-Free-Cash-Flow 25.56
HAE's Price-to-Free-Cash-Flow is ranked higher than
64% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. HAE: 25.56 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HAE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.8  Med: 33.62 Max: 497.33
Current: 25.56
15.8
497.33
Price-to-Operating-Cash-Flow 13.35
HAE's Price-to-Operating-Cash-Flow is ranked higher than
76% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. HAE: 13.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HAE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.91  Med: 14.06 Max: 25.67
Current: 13.35
9.91
25.67
EV-to-EBITDA 33.21
HAE's EV-to-EBITDA is ranked lower than
55% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. HAE: 33.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
HAE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.1  Med: 12.65 Max: 61.4
Current: 33.21
7.1
61.4
Shiller PE Ratio 58.89
HAE's Shiller PE Ratio is ranked lower than
53% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. HAE: 58.89 )
Ranked among companies with meaningful Shiller PE Ratio only.
HAE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 25.95  Med: 35.73 Max: 61.71
Current: 58.89
25.95
61.71
Current Ratio 2.42
HAE's Current Ratio is ranked lower than
52% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. HAE: 2.42 )
Ranked among companies with meaningful Current Ratio only.
HAE' s Current Ratio Range Over the Past 10 Years
Min: 2.09  Med: 2.91 Max: 4.92
Current: 2.42
2.09
4.92
Quick Ratio 1.58
HAE's Quick Ratio is ranked lower than
64% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. HAE: 1.58 )
Ranked among companies with meaningful Quick Ratio only.
HAE' s Quick Ratio Range Over the Past 10 Years
Min: 1.28  Med: 2.04 Max: 4.17
Current: 1.58
1.28
4.17
Days Inventory 134.66
HAE's Days Inventory is ranked lower than
59% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. HAE: 134.66 )
Ranked among companies with meaningful Days Inventory only.
HAE' s Days Inventory Range Over the Past 10 Years
Min: 89.4  Med: 110.49 Max: 156.73
Current: 134.66
89.4
156.73
Days Sales Outstanding 62.89
HAE's Days Sales Outstanding is ranked higher than
52% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. HAE: 62.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
HAE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.47  Med: 67.5 Max: 84.99
Current: 62.89
58.47
84.99
Days Payable 30.90
HAE's Days Payable is ranked lower than
75% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. HAE: 30.90 )
Ranked among companies with meaningful Days Payable only.
HAE' s Days Payable Range Over the Past 10 Years
Min: 26.02  Med: 31.53 Max: 41.58
Current: 30.9
26.02
41.58

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 196.19
HAE's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. HAE: 196.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HAE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4  Med: 6.14 Max: 196.19
Current: 196.19
4
196.19
Price-to-Tangible-Book 6.10
HAE's Price-to-Tangible-Book is ranked lower than
62% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. HAE: 6.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HAE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.9  Med: 3.55 Max: 12.2
Current: 6.1
1.9
12.2
Price-to-Intrinsic-Value-Projected-FCF 2.13
HAE's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
51% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. HAE: 2.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HAE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.27  Med: 1.62 Max: 2.42
Current: 2.13
1.27
2.42
Price-to-Median-PS-Value 1.03
HAE's Price-to-Median-PS-Value is ranked higher than
66% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. HAE: 1.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HAE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62  Med: 1 Max: 1.41
Current: 1.03
0.62
1.41
Earnings Yield (Greenblatt) % -0.83
HAE's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. HAE: -0.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HAE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.83  Med: 5.9 Max: 11.2
Current: -0.83
-0.83
11.2
Forward Rate of Return (Yacktman) % -13.71
HAE's Forward Rate of Return (Yacktman) % is ranked lower than
91% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. HAE: -13.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HAE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16  Med: 8.9 Max: 17.5
Current: -13.71
-16
17.5

More Statistics

Revenue (TTM) (Mil) $886.1
EPS (TTM) $ -0.51
Beta0.95
Short Percentage of Float5.23%
52-Week Range $27.53 - 43.62
Shares Outstanding (Mil)52.46

Analyst Estimate

Mar18 Mar19
Revenue (Mil $) 891 922
EPS ($) 1.59 1.82
EPS without NRI ($) 1.59 1.82
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.00%
Dividends per Share ($)
» More Articles for HAE

Headlines

Articles On GuruFocus.com
Haemonetics Sets Date for Investor / Analyst Meeting - June 19, 2017 May 22 2017 
Haemonetics 4th Quarter and Fiscal Year 2017 Earnings Release and Fiscal Year 2018 Guidance Availabl May 08 2017 
Haemonetics Sets Date for Publishing 4th Quarter and Full Fiscal Year 2017 Results and for Providing Apr 26 2017 
Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer Feb 09 2017 
Weekly CEO Buys Highlights Aug 15 2016 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Meridian Contrarian Fund Second Quarter Commentary Sep 08 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders Jul 22 2014 
This Blood Management Company Can Be A Safe Investment Jul 13 2014 

More From Other Websites
Haemonetics Corp. :HAE-US: Earnings Analysis: 2017 By the Numbers : May 26, 2017 May 26 2017
Haemonetics Corp (HAE) Files 10-K for the Fiscal Year Ended on March 31, 2017 May 24 2017
Haemonetics Sets Date for Investor / Analyst Meeting - June 19, 2017 May 22 2017
Haemonetics Corp. – Value Analysis (NYSE:HAE) : May 19, 2017 May 19 2017
Haemonetics Corp. breached its 50 day moving average in a Bearish Manner : HAE-US : May 18, 2017 May 18 2017
Edited Transcript of HAE earnings conference call or presentation 8-May-17 12:00pm GMT May 12 2017
Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View May 09 2017
Haemonetics reports 4Q loss May 08 2017
Haemonetics 4th Quarter and Fiscal Year 2017 Earnings Release and Fiscal Year 2018 Guidance... May 08 2017
[$$] The Add-On Deal Roundup: April 28 Apr 28 2017
Haemonetics Sets Date for Publishing 4th Quarter and Full Fiscal Year 2017 Results and for Providing... Apr 26 2017
Haemonetics' Plasma Group Strong, Blood Center Group a Drag Apr 12 2017
Haemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : March 24, 2017 Mar 24 2017
Why Is Haemonetics (HAE) Up 3.5% Since the Last Earnings Report? Mar 09 2017
RBC Says These Top Health Care Stocks Could Be 2017 Takeover Candidates Mar 02 2017
Haemonetics Corp. :HAE-US: Earnings Analysis: Q3, 2017 By the Numbers : February 9, 2017 Feb 09 2017
Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates Feb 07 2017
Edited Transcript of HAE earnings conference call or presentation 6-Feb-17 1:00pm GMT Feb 06 2017
Haemonetics tops Street 3Q forecasts Feb 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)